Skip to content
Inciteful Med

The Many Faces of PSP: Understanding Subtypes and Progression

Last updated:

Progressive Supranuclear Palsy (PSP) is a family of related neurological conditions caused by tau protein buildup in the brain. The specific subtype, such as the aggressive Richardson Syndrome or the milder PSP-Parkinsonism, determines a patient's initial symptoms, treatment response, and life expectancy.

Key Takeaways

  • • PSP is a family of related subtypes determined by where tau protein builds up in the brain.
  • • Richardson Syndrome (PSP-RS) is the classic and most aggressive form, characterized by early falls and difficulty looking up and down.
  • • PSP-Parkinsonism (PSP-P) is a milder form that progresses more slowly and can temporarily respond to Parkinson's medications.
  • • Rare variants of PSP can primarily affect personality, speech, or cause gait freezing.
  • • Doctors identify your subtype by tracking symptom timing, medication response, and using specialized MRI measurements.

When you hear the term Progressive Supranuclear Palsy (PSP), it is natural to think of it as one single condition. However, doctors now recognize that PSP is actually a “family” of related subtypes [1][2]. While they all involve the same tau protein building up in the brain, where that protein settles determines which symptoms appear first and how quickly the disease progresses [3][2].

The “Classic” Form: Richardson Syndrome (PSP-RS)

Richardson Syndrome is often called “classic PSP” because it follows the most well-known pattern of the disease [4]. It is usually the most aggressive form.

  • Defining Features: Early and frequent falls (especially backward), significant difficulty looking up and down (vertical gaze palsy), and changes in thinking and behavior [4][5].
  • Progression: This subtype tends to move more quickly, with an average survival of 5 to 7 years from the first symptoms [6][7].
  • Pathology: In this form, the tau protein is mostly concentrated in deep, “subcortical” areas of the brain like the brainstem [3][8].

The “Milder” Form: PSP-Parkinsonism (PSP-P)

This subtype is frequently misdiagnosed as Parkinson’s disease because it looks so similar in the early years [4][9].

  • Defining Features: It may start with a tremor or stiffness on just one side of the body [4]. Unlike the classic form, these patients often see a moderate improvement when taking Parkinson’s medications like levodopa for the first year or two [4][9].
  • Progression: PSP-P usually has a more gradual deterioration and a longer life expectancy, often 8 to 12 years [6][7]. Major milestones—like needing a wheelchair or having severe swallowing issues—typically happen much later than in Richardson Syndrome [10][11].

Other Rare Variants

While PSP-RS and PSP-P are the most common, there are several other “atypical” ways PSP can present:

Subtype Key Symptom What it looks like
PSP-F (Frontal) Personality Changes Early changes in behavior, poor judgment, or loss of interest (apathy) [12][13].
PSP-SL (Speech/Language) Communication Loss Significant difficulty finding words or using proper grammar [2][14].
PSP-PGF (Gait Freezing) “Frozen” Feet A primary symptom where the feet feel “glued” to the floor, making it hard to start walking [15].
PSP-CBS (Corticobasal) One-Sided Loss Severe stiffness or “clumsiness” in just one arm or leg [16][17].

How Doctors Determine Your Subtype

There is no single blood test for these subtypes. Instead, doctors use a “watchful waiting” approach, looking at:

  1. Symptom Timing: Did balance issues start in year 1 (likely RS) or year 5 (likely P)? [18]
  2. Medication Response: Did the patient respond to levodopa? [19]
  3. Advanced Imaging: Specialists use specialized MRI measurements (like the Magnetic Resonance Parkinsonism Index) to look for specific patterns of brain shrinkage [20][21].

Knowing the subtype is helpful because it allows you and your family to plan for the future with a more accurate timeline of what to expect [10][9]. Over time, some of the milder forms (like PSP-P) may eventually begin to look more like the classic Richardson Syndrome [9][4].

Return to the Main Guide

Frequently Asked Questions

What is the most common type of PSP?
The most common and well-known form is Richardson Syndrome, often called classic PSP. It typically involves early backward falls, difficulty looking up and down, and a faster rate of disease progression.
How is PSP-Parkinsonism different from classic PSP?
PSP-Parkinsonism often starts with tremors or stiffness on one side, closely resembling Parkinson's disease. Patients with this subtype usually experience a slower disease progression and may temporarily respond to Parkinson's medications like levodopa.
How do doctors diagnose my specific PSP subtype?
Doctors determine your subtype by monitoring when specific symptoms appear, such as whether balance issues start early or years later. They also check if you respond to Parkinson's medications and may use advanced MRI scans to look for specific patterns of brain shrinkage.
Will my PSP subtype change over time?
While your initial subtype defines how the disease begins, milder variants often evolve over time. For example, in the later stages of the disease, PSP-Parkinsonism frequently progresses to look much more like classic Richardson Syndrome.

Questions for Your Doctor

  • • Based on my symptoms, which subtype of PSP do you think I have, and how does that affect my long-term outlook?
  • • Is the fact that I responded well to Parkinson's medication (or didn't) a key factor in identifying my subtype?
  • • How frequently should we be re-evaluating my subtype as my symptoms change over time?
  • • Can you explain the difference in the rate of progression between Richardson's Syndrome and PSP-Parkinsonism?
  • • Are there specific therapies (like speech or physical therapy) that are more critical for my particular subtype?

Questions for You

  • • Did your symptoms start with balance and eye problems, or did you notice a tremor and stiffness on one side first?
  • • How quickly have you reached major changes, such as needing a walker or having significant trouble speaking?
  • • Have you noticed changes in your personality or your ability to find words, in addition to movement issues?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect.

    Nasri A, Sghaier I, Neji A, et al.

    Journal of movement disorders 2024; (17(2)):158-170 doi:10.14802/jmd.23178.

    PMID: 38290492
  2. 2

    Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.

    Whitwell JL, Tosakulwong N, Botha H, et al.

    NeuroImage. Clinical 2020; (25()):102152 doi:10.1016/j.nicl.2019.102152.

    PMID: 31935638
  3. 3

    Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.

    Orlandi F, Carlos AF, Ali F, et al.

    Brain communications 2024; (6(2)):fcae113 doi:10.1093/braincomms/fcae113.

    PMID: 38660629
  4. 4

    "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.

    Necpál J, Borsek M, Jeleňová B

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):4927-4936 doi:10.1007/s10072-021-05601-8.

    PMID: 34532773
  5. 5

    Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report.

    Korucu I, Karakoyun Alpay T

    Cureus 2025; (17(12)):e98307 doi:10.7759/cureus.98307.

    PMID: 41340976
  6. 6

    Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.

    Shoeibi A, Litvan I, Tolosa E, et al.

    Parkinsonism & related disorders 2019; (66()):87-93 doi:10.1016/j.parkreldis.2019.07.010.

    PMID: 31307919
  7. 7

    Progressive Supranuclear Palsy-A Global Review.

    Kukkle PL, Neupane R, Pantelyat A, et al.

    Movement disorders clinical practice 2025; doi:10.1002/mdc3.70338.

    PMID: 40898879
  8. 8

    Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.

    Stejskalova Z, Rohan Z, Rusina R, et al.

    BMC neurology 2019; (19(1)):42 doi:10.1186/s12883-019-1270-1.

    PMID: 30894142
  9. 9

    Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.

    Alster P, Kutyłowski M, Madetko-Alster N

    Diagnostics (Basel, Switzerland) 2025; (15(8)) doi:10.3390/diagnostics15080945.

    PMID: 40310371
  10. 10

    Subtypes of PSP and Prognosis: A Retrospective Analysis.

    Mahale RR, Krishnan S, Divya KP, et al.

    Annals of Indian Academy of Neurology 2021; (24(1)):56-62 doi:10.4103/aian.AIAN_611_20.

    PMID: 33911380
  11. 11

    Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials.

    Marchand F, Blaise AS, Defebvre L, et al.

    Journal of Parkinson's disease 2024; (14(8)):1652-1658 doi:10.1177/1877718X241291996.

    PMID: 39957197
  12. 12

    Progressive supranuclear palsy with predominant frontal presentation exhibiting progressive nonfluent aphasia due to crossed aphasia.

    Ono Y, Higashida K, Yoshikura N, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2022; (42(3)):232-238 doi:10.1111/neup.12805.

    PMID: 35434847
  13. 13

    Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy.

    Sakae N, Josephs KA, Litvan I, et al.

    Movement disorders : official journal of the Movement Disorder Society 2019; (34(11)):1655-1662 doi:10.1002/mds.27816.

    PMID: 31433871
  14. 14

    Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant.

    Gatto RG, Martin PR, Ali F, et al.

    NeuroImage. Clinical 2022; (35()):103030 doi:10.1016/j.nicl.2022.103030.

    PMID: 35597031
  15. 15

    An Unusual Presentation of Progressive Supranuclear Palsy.

    Dec-Cwiek M, Boczarska-Jedynak M, Pera J

    Neurology India 2021; (69(6)):1789-1793 doi:10.4103/0028-3886.333499.

    PMID: 34979690
  16. 16

    Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants.

    Black JA, Pham NTT, Ali F, et al.

    Journal of neurology 2024; (271(7)):4267-4280 doi:10.1007/s00415-024-12350-z.

    PMID: 38632125
  17. 17

    Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.

    Ono D, Sekiya H, Ghayal NB, et al.

    Journal of neurology 2025; (272(10)):704 doi:10.1007/s00415-025-13459-5.

    PMID: 41107539
  18. 18

    Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly.

    Fernández-Ferreira R, García-Santos RA, Rodríguez-Violante M, et al.

    Revista espanola de geriatria y gerontologia 2019; (54(5)):251-256 doi:10.1016/j.regg.2019.04.002.

    PMID: 31324404
  19. 19

    Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses.

    Ye L, Sani SS, Veith Sanches L, et al.

    Brain sciences 2024; (14(10)) doi:10.3390/brainsci14100991.

    PMID: 39452005
  20. 20

    Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study.

    Quattrone A, Morelli M, Quattrone A, et al.

    Parkinsonism & related disorders 2020; (72()):1-6 doi:10.1016/j.parkreldis.2020.01.019.

    PMID: 32036297
  21. 21

    Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting.

    Cooperrider J, Bluett B, Jones SE

    Clinical parkinsonism & related disorders 2020; (3()):100033 doi:10.1016/j.prdoa.2020.100033.

    PMID: 34316619

This page explains Progressive Supranuclear Palsy (PSP) subtypes and disease progression for educational purposes. Always consult your neurologist for a formal diagnosis and personalized care plan.

Stay up to date

Get notified when new research about Progressive supranuclear palsy is published.

No spam. Unsubscribe anytime.